Intravitreal Bevacizumab With or Without Triamcinolone for
Refractory Diabetic Macular...

J 2010

Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...

SYNEK, Svatopluk and Bozo VOJNIKOVIC

Basic information

Original name

Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...

Authors

SYNEK, Svatopluk (203 Czech Republic, guarantor, belonging to the institution) and Bozo VOJNIKOVIC (191 Croatia)

Edition

Collegium Antropologicum, Zagreb, 2010, 0350-6134

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Croatia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 0.491

RIV identification code

RIV/00216224:14110/10:00061165

Organization unit

Faculty of Medicine

UT WoS

000283961100021

Keywords in English

bevacizumab; diabetic macular oedema

Abstract

V originále

We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). Improvement of BCVA was initiated at weeks 6 and 12 in the IVB/IVT and IVB groups respectively. In terms of BCVA change compared to the baseline at 24 weeks, the differences between the IVB and the IVB/IVT groups (p=0.006) were significant. Anterior Chamber reaction was noticed in six (20%) and six (20%) eyes respectively in the IVB and IVB/IVT groups the day after injection, and it resolved with no sequel. Elevation of IOP occurred in two eyes (6%) in the IVB/IVT group. Intravitreal injections of Bevacizumab had a beneficial effect on refractory DME in terms of CMT reduction and BCVA improvement. Addition of triamcinolone in the injection seemed to induce earlier visual improvement; however, it did not show any significant additive effect later during follow-up.

Citovat

SYNEK, Svatopluk and Bozo VOJNIKOVIC. Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... Collegium Antropologicum. Zagreb, 2010, vol. 34, Suppl. 2, p. 99-103. ISSN 0350-6134.

@article{1067629,
   author = {Synek, Svatopluk and Vojnikovic, Bozo},
   article_location = {Zagreb},
   article_number = {Suppl. 2},
   keywords = {bevacizumab; diabetic macular oedema},
   language = {eng},
   issn = {0350-6134},
   journal = {Collegium Antropologicum},
   title = {Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...},
   volume = {34},
   year = {2010}
}

TY  - JOUR
ID  - 1067629
AU  - Synek, Svatopluk - Vojnikovic, Bozo
PY  - 2010
TI  - Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular...
JF  - Collegium Antropologicum
VL  - 34
IS  - Suppl. 2
SP  - 99-103
EP  - 99-103
SN  - 03506134
KW  - bevacizumab
KW  - diabetic macular oedema
N2  - We evaluate the effect of intravitreal injections of Bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractor), diabetic macular oedema (DME). Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB (1.25 mg/0.05 mL) or combined IVB and IVT (1.25 mg/0.05 mL and 2 mg/0.05 mL respectively). The primary outcome measure was change in central macular thickness (CMT). Secondary outcome measures were change in best-corrected logMAR visual acuity (BCVA) and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB/IVT groups. At week 24, CMT change compared to the baseline was -95.7 mu m (95% CI, -172.2 to -19.26) in the IVB group and -92.1 mu m (95% CI, -154.4 to -29.7) in the IVB/IVT group. There was not a significant difference between the IVB and the IVB/IVT groups (p=0.022). Improvement of BCVA was initiated at weeks 6 and 12 in the IVB/IVT and IVB groups respectively. In terms of BCVA change compared to the baseline at 24 weeks, the differences between the IVB and the IVB/IVT groups (p=0.006) were significant. Anterior Chamber reaction was noticed in six (20%) and six (20%) eyes respectively in the IVB and IVB/IVT groups the day after injection, and it resolved with no sequel. Elevation of IOP occurred in two eyes (6%) in the IVB/IVT group. Intravitreal injections of Bevacizumab had a beneficial effect on refractory DME in terms of CMT reduction and BCVA improvement. Addition of triamcinolone in the injection seemed to induce earlier visual improvement; however, it did not show any significant additive effect later during follow-up.
ER  -

SYNEK, Svatopluk and Bozo VOJNIKOVIC. Intravitreal Bevacizumab With or Without Triamcinolone for Refractory Diabetic Macular... \textit{Collegium Antropologicum}. Zagreb, 2010, vol.~34, Suppl. 2, p.~99-103. ISSN~0350-6134.

Detailed Information on Publication Record